From the article:
“Obesity is very common in men with testosterone deficiency (hypogonadism),” said lead study author Karim Haider, M.D., a urologist and andrologist in private practice in Bremerhaven, Germany.
[…]
The 462 (57.4 percent) patients with obesity were given the choice whether to be treated with long-term testosterone therapy (TTh) with testosterone undecanoate injections (TU) 1,000 mg every 12 weeks. Of these, 273 opted to receive testosterone, and the 189 who declined treatment served as controls.
Over 10 years, the testosterone-treated men lost 20.3 percent of their baseline weight (50.5 lb; 22.9 kg); their waist circumference dropped by 12.5 cm (4.9 in). BMI decreased by 7.3 kg/m2, and the waist-to-height ratio decreased by 0.07.
By contrast, the untreated men gained 3.9 percent of their baseline weight (3.2 kg; 7.1 lb), and their waist size increased by 4.6 cm (1.8 in). In this group, BMI increased by 0.9 kg/m2, and waist-to-height ratio increased by 0.03.
During this time, 12 (4.4 percent) men in the testosterone group died, while in the untreated control group, 57 deaths (30.2 percent), 47 myocardial infarctions (24.9 percent) and 44 strokes (23.3 percent) occurred.